Aileron is a small 14-employee Cambridge biotech company who are developing a cancer drug designed to kickstart an important tumor-suppressing gene.
In a federal filing it has applied to trade on the Nasdaq under the ticker ALRN. and plans to raise up to $69 million in an IPO. The filing came one day after another Cambridge cancer drug developer, Mersana Therapeutics, announced plans to raise up to $75 million in an IPO.
Contact: Joseph Yanchik (Aileron President and CEO)
Cambridge-based Akcea Therapeutics, which disclosed a proposed $100 million IPO a couple of months ago (March 2017).
Following a difficult 2016, Jounce Therapeutics (JNCE) raised just over $10 million in January and remains the only local biotech company to reach IPO this year.